Grifols (ES:GRF) has released an update.
Grifols S.A. has announced a restatement of its Consolidated Interim Financial Statements for the first half of 2024 due to incorrect accounting, affecting the reported results and EBITDA figures. The restatements are a result of reclassifying a joint venture with ImmunoTek as a joint operation and correcting the accounting treatment of a non-controlling interest in Shanghai RAAS Blood Products Co. Limited. Despite the restatements, which have significantly impacted the company’s reserves and investments, the auditor Deloitte Auditores, S.L. has confirmed that the interim financial statements were prepared in accordance with International Accounting Standards.
For further insights into ES:GRF stock, check out TipRanks’ Stock Analysis page.
